AI / ML Innovations Stock Price, News & Analysis

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced a second pilot study for its Alakin healthcare management platform, launching in Paris, France. This study targets Parkinson's disease, affecting 200,000 individuals in France. Alakin features a user-friendly clinical dashboard and a mobile app for patient interaction, available in five languages. The platform aims to enhance productivity in healthcare settings through customizable care pathways and is set to deploy in various regions, including North America. The trial will integrate digital biomarkers for monitoring patient progress.

AI/ML Innovations Inc. announces the successful results of its Annual General Meeting held on July 27, 2022. A total of 5,412,712 common shares were voted, representing 15.5% of issued shares, achieving quorum. Key resolutions passed include the election of 4 Directors: Tim Daniels, Nick Watters, Randy Duguay, and Bruce Matichuk, the appointment of Baker Tilly Canada as auditors, and the approval of the Company's Stock Option Plan. For more details, shareholders can refer to the Company's profile on SEDAR.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announces the upcoming launch of Alakin, a comprehensive healthcare management platform developed by its subsidiary Tech2Heal. This SaaS solution, built on FHIR standards, aims to improve patient engagement and optimize workflows in healthcare settings. A pilot study will commence at a 30,000-patient facility in Paris, with full deployment planned for August 2022. Alakin will streamline patient care processes, potentially leading to significant time and cost savings for healthcare providers.

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a finalist in the prestigious i-Nov Innovation Contest. This recognition highlights the innovative potential of its Qookka digital therapy for mental health disorders, with less than 10% of entries making the cut. The contest, backed by the Programme d'Investissements d'Avenir in France, offers up to €5M in co-financing for winners. Qookka utilizes advanced AI algorithms and digital biomarkers for enhanced patient support and monitoring.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced a marketing services agreement with Octagon Media Corp to enhance its digital media presence. The contract, lasting three months, involves monthly payments of US$25,000 and the issuance of 500,000 stock options at CAD$0.20. Additionally, the company granted 800,000 options to management at the same exercise price. Through strategic partnerships and a focus on AI and ML technologies, AI/ML aims to drive growth in the healthcare sector.

AI/ML Innovations Inc. announced a License Agreement with MedWatch Technologies, Inc. to utilize patented health management technology and AI software for diabetes monitoring solutions. MedWatch will pay Health Gauge an annual fee of US$120,000 plus a 2% royalty on gross sales. With diabetes-related medical costs in the US at $327 billion annually, the partnership aims to improve patient outcomes through non-invasive monitoring tools. The agreement spans an initial term of 7 years, with a US$2 million termination fee.

AI/ML Innovations Inc. announced a license agreement with MedWatch Technologies for its patented health management technology, targeting the $327 billion US diabetes market. MedWatch will pay an annual fee of US$120,000 plus a 2% royalty on gross sales, projected to be US$5.00 to US$8.00 per device. The agreement has an initial term of 7 years with automatic renewals and includes a US$2 million early termination fee. This strategic partnership aims to enhance diabetes management through innovative blood glucose monitoring solutions.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed a non-brokered private placement, issuing 4 million units at $0.15 per unit, resulting in $600,000 in gross proceeds. Each unit consists of one common share and one share purchase warrant, exercisable at $0.20 for 12 months. The funds will support platform deployment with healthcare clients and general operating expenses. The company incurred $25,337.81 in finder's fees for this offering.